<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981457</url>
  </required_header>
  <id_info>
    <org_study_id>MS-196-2021</org_study_id>
    <nct_id>NCT04981457</nct_id>
  </id_info>
  <brief_title>Comparative Study Between Combined Vaginal Misoprostol</brief_title>
  <acronym>comparative</acronym>
  <official_title>Comparative Study Between Combined Vaginal Misoprostol With Isosorbide-5-Mononitrate Versus Misoprostol Alone For Induction Of The First Trimester Missed Abortion A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Comparative study between Combined Vaginal Misoprostol with Isosorbide-5-Mononitrate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Comparative study between Combined Vaginal Misoprostol with Isosorbide-5-Mononitrate versus&#xD;
      Misoprostol Alone For Induction Of The first trimester Missed Abortion A Randomized Clinical&#xD;
      Trial&quot;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction to abortion interval</measure>
    <time_frame>6 months</time_frame>
    <description>Induction to abortion interval: the Duration interval between the beginning of the induction and beginning of cervical ripening assessed by cervical examination(cervix become soft and start to dilate) and uterine contractions leading to complete expulsion of the abortus spontaneous and if cervical ripening isn't occur by maximum doses the investigators will make surgical evacuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of the doses</measure>
    <time_frame>6 months</time_frame>
    <description>the Number of the doses of misoprostol needed to complete expulsion (spontaneous or surgical)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Missed Abortion</condition>
  <arm_group>
    <arm_group_label>patients who recieve misoprostol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A (n =30 ) will receive only vaginal Misoprostol 800mcg (4 tablets Cytotec 200mcg ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or uterine contractions or bleeding assessed by the same doctor who made evaluation at the beginning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients who recieve misoprostol and iso sorbide mononitrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B (n =30 ) will receive combined vaginal Misoprostol 800mcg (4 tablets Cytotec ) ) every 3 hours to a maximum of two doses or until reaching cervical ripening or start of uterine contractions or bleeding. with Isosorbide-5-mononitrate (20 mg). Effox 20 mg )once at the beginning with misoprostol until reaching cervical ripening or start of and uterine contractions assessed by the same doctor who made the evaluation at the beginning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol and iso sorbide mononitrates</intervention_name>
    <description>drug</description>
    <arm_group_label>patients who recieve misoprostol alone</arm_group_label>
    <arm_group_label>patients who recieve misoprostol and iso sorbide mononitrate</arm_group_label>
    <other_name>misotac and effox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Maternal Age 18 - 35 years.&#xD;
&#xD;
          -  Gestational age first trimester of pregnancy (between 5-13 weeks).&#xD;
&#xD;
          -  Missed abortion confirmed by ultrasound.&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  Normal uterus and cervix on clinical examination.&#xD;
&#xD;
          -  Cervix is not dilated.&#xD;
&#xD;
          -  No vaginal bleeding.&#xD;
&#xD;
        Exclusion Criteria:- Evidences suggesting start of spontaneous abortion and previous trial&#xD;
        to induce abortion.&#xD;
&#xD;
          -  Presence of uterine contraction or bleeding,&#xD;
&#xD;
          -  Multi-fetal pregnancy.&#xD;
&#xD;
          -  Suspicion of septic abortion.&#xD;
&#xD;
          -  History of Previous cervical surgery or manipulation. Ex: cervical tear , cervical&#xD;
             cauterization .&#xD;
&#xD;
          -  Uterine anomaly.&#xD;
&#xD;
          -  Presence of IUD( intrauterine device) in situ&#xD;
&#xD;
          -  Underlying medical diseases.Ex:diabetes mellitus,hypertension&#xD;
&#xD;
          -  History of allergy or adverse effects to vaginally administered medication e.g.&#xD;
             isosorbide -5- mononitrate&#xD;
&#xD;
          -  Those unwilling to participate in the trial&#xD;
&#xD;
          -  Higher order cesarean section(more than three&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamed shalaby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo u</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo U</name>
      <address>
        <city>Cairo</city>
        <state>Married</state>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Arteaga-Troncoso G, Villegas-Alvarado A, Belmont-Gomez A, Martinez-Herrera FJ, Villagrana-Zesati R, Guerra-Infante F. Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of conception. BJOG. 2005 Dec;112(12):1615-9.</citation>
    <PMID>16305563</PMID>
  </reference>
  <reference>
    <citation>Carlsson I, Breding K, Larsson PG. Complications related to induced abortion: a combined retrospective and longitudinal follow-up study. BMC Womens Health. 2018 Sep 25;18(1):158. doi: 10.1186/s12905-018-0645-6.</citation>
    <PMID>30253769</PMID>
  </reference>
  <reference>
    <citation>Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017 Jan 31;1:CD007223. doi: 10.1002/14651858.CD007223.pub4. Review.</citation>
    <PMID>28138973</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Kholod Mohamed Mahmoud Mousa Elkholy</investigator_full_name>
    <investigator_title>resident of obstetrics and gynacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT04981457/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

